Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) had its price objective lowered by investment analysts at Guggenheim from $17.00 to $13.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim‘s target price would indicate a potential upside of 180.17% from the company’s current price.
Other analysts have also issued research reports about the stock. Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, November 9th. Roth Capital reissued a “buy” rating and set a $11.00 target price on shares of Entrada Therapeutics in a report on Wednesday, August 12th. HC Wainwright restated a “neutral” rating on shares of Entrada Therapeutics in a research report on Monday, October 19th. UBS Group restated a “neutral” rating on shares of Entrada Therapeutics in a research report on Monday, October 19th. Finally, Weiss Ratings raised shares of Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $16.75.
Read Our Latest Stock Analysis on TRDA
Entrada Therapeutics Stock Performance
Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $0.07. Entrada Therapeutics had a negative return on equity of 64.00% and a negative net margin of 4,057.98%. The business had revenue of $0.91 million for the quarter, compared to analyst estimates of $2.30 million. On average, analysts anticipate that Entrada Therapeutics will post -4.12 EPS for the current year.
Insider Buying and Selling
In other Entrada Therapeutics news, major shareholder Bioventures 2014 L.P. Mpm sold 26,522 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $7.54, for a total value of $199,975.88. Following the sale, the insider directly owned 4,332,917 shares of the company’s stock, valued at $32,670,194.18. This trade represents a 0.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 192,500 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $7.41, for a total value of $1,426,425.00. Following the completion of the sale, the insider directly owned 3,913,952 shares in the company, valued at $29,002,384.32. This represents a 4.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 495,947 shares of company stock valued at $3,600,470 in the last 90 days. Insiders own 9.49% of the company’s stock.
Hedge Funds Weigh In On Entrada Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of TRDA. BlackRock Inc. bought a new position in Entrada Therapeutics in the 2nd quarter worth about $19,013,000. Nantahala Capital Management LLC acquired a new stake in shares of Entrada Therapeutics in the second quarter valued at approximately $2,212,232. 5AM Venture Management LLC acquired a new stake in shares of Entrada Therapeutics in the second quarter valued at approximately $29,854,949. GSA Capital Partners LLP bought a new stake in shares of Entrada Therapeutics during the second quarter valued at approximately $648,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Entrada Therapeutics during the second quarter valued at approximately $582,000. Institutional investors and hedge funds own 86.39% of the company’s stock.
About Entrada Therapeutics
Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.
Further Reading
- Five stocks we like better than Entrada Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
